Pharma Stocks Outlook for the week - 06 to 10.03.2017
Pharma Stocks Outlook for the week - 06 to 10.03.2017
( www.rupeedesk.in )
The shares of most pharmaceutical companies are likely to rise next week as investors expect strong
growth in the domestic market, and as concerns over their US business is seen easing. Companies
reported mixed growth in Oct-Dec due to disruption from demonetisation, Axis Capital said in its report. The impact of demonetisation is expected to reduce in Jan-Mar, and will fade out by the beginning of the next fiscal. In the US market, while there is unpredictability over President Donald Trump's policies, we see his comments about reducing drug prices as positive for Indian generic drug makers. Another factor due to which market participants may focus on companies with less US exposure is regulatory issues. Sun Pharmaceutical Industries' Halol facility and four units of erstwhile-Ranbaxy Laboratories are due for a re-inspection by US Food and Drug Administration. While the Halol plant received a warning letter from the US FDA in December 2015, the four Ranbaxy units have been under import alert for as long as a decade. Sun Pharma completed the acquisition of Ranbaxy in 2015.
Free Intraday Tips : Join Our Whatsapp No : 9841986753
Free Commodity Tips : Join our Whatsapp No : 9094047040
Pharma Stocks Outlook for the week - 06 to 10.03.2017
( www.rupeedesk.in )
The shares of most pharmaceutical companies are likely to rise next week as investors expect strong
growth in the domestic market, and as concerns over their US business is seen easing. Companies
reported mixed growth in Oct-Dec due to disruption from demonetisation, Axis Capital said in its report. The impact of demonetisation is expected to reduce in Jan-Mar, and will fade out by the beginning of the next fiscal. In the US market, while there is unpredictability over President Donald Trump's policies, we see his comments about reducing drug prices as positive for Indian generic drug makers. Another factor due to which market participants may focus on companies with less US exposure is regulatory issues. Sun Pharmaceutical Industries' Halol facility and four units of erstwhile-Ranbaxy Laboratories are due for a re-inspection by US Food and Drug Administration. While the Halol plant received a warning letter from the US FDA in December 2015, the four Ranbaxy units have been under import alert for as long as a decade. Sun Pharma completed the acquisition of Ranbaxy in 2015.
